Masayoshi Harigai, MD, PhD is Professor and Chairperson of Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University, Tokyo, Japan. He graduated from National Defense Medical College and received PhD from Keio University in 1991. He served as Professor of Department of Pharmacovigilance at Graduate School of Tokyo Medical and Dental University between 2007 and 2015. After returning to Tokyo Women’s University in 2015 as an Endowed Professor, he was installed in the present position in 2019. Professor Harigai is the principal investigator of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS), clinical trial of tocilizumab for ANCA-associated vasculitis, and 2020 Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis. He has been serving as a board member of Japan College of Rheumatology since 2018.